// App-Quantinova.ai

539 : Concurrent Use of Blinatumomab and Donor Lymphocyte Infusion (DLI) for Treatment of Relapsed Precursor B Cell Acute Lymphoblastic Leukemia (pre B ALL) after Allogeneic Hematopoietic Cell Transplant (HCT)

Researchers

Presenter

  • Masumi Ueda

Principal Investigators

  • Hillard M. Lazarus

  • Benjamin Tomlinson

  • Richard Creger

  • Merle Kolk

  • Marcos de Lima

  • Brenda Cooper

Medical Centers

  • Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Graft-versus-host disease

Biomarkers

  • Breakpoint Cluster Region

  • Ph chromosome

  • Cluster of Differentiation 2AP

Drug/Treatment

  • Blinatumomab

  • Clofarabine

  • fludarabine tablet

  • Busulfan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved